ReviewJournal of translational medicine2026
Regulation of G protein-coupled receptor kinase 2 and its role in tumors.
Review in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundG protein-coupled receptor kinase 2(GRK2) is a pivotal regulator of G protein-coupled receptor (GPCR) signal desensitization. It is increasingly recognized for its involvement in the pathogenesis of various malignancies through non-canonical signaling pathways. MAIN BODY: This review systematically integrates the multilevel regulatory mechanisms of GRK2, encompassing its structure and function, key post-translational modifications (e.g. ubiquitination and phosphorylation), and dynamic subcellular localization. Analysis reveals that GRK2 exerts intricate and bidirectional regulatory roles in several solid tumors, including glioma, colorectal cancer, breast cancer, and lung cancer, with its mechanisms of action showing significant variability depending on tumor type and microenvironment. Emerging therapeutic strategies, such as small-molecule inhibitors targeting GRK2 and tissue-specific gene-editing models, show promising potential as precise oncology interventions.
conclusionsDespite the considerable promise of GRK2-targeted therapies, their clinical translation faces critical challenges, including inadequate tissue selectivity and the risk of drug resistance. Therefore, future research should focus on overcoming these scientific hurdles to realize the full clinical application value of modulating GRK2 in oncology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.